Advanced Prostate Cancer VL

Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland

Details
Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer. This study is part of a series of studies looking at the role of low carbohydrate diets in prostate cancer. The study involved taking men with rising PSA after failed s...

The Statisticians Perspective on Methods of Comparing Prostate Cancer Clinical Trial Data - Matthew Sydes

Details
Matthew Sydes joins Alicia Morgans to share his perspective on the data supporting a patient’s decision whether to use docetaxel or whether to use AR pathway inhibitors at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). The two discuss the direct and indirect methods of trial comparison and examine the data from trials that reported on docetaxel as well as the abiraterone clinical...

AR Indifferent Subtype Tumors in Prostate Cancer - Ana Aparicio

Details
Ana Aparicio joins Alicia Morgans at ASCO GU 2020 to discuss her work with AR indifferent tumors in the field of prostate cancer. Among the topics discussed, Dr. Aparicio stressed the importance of understanding clinical features and the development of a profile of this AR indifferent subtype in order to allow for easier identification. The two further discuss the research and ongoing clinical tri...

Supportive Therapy in Androgen Deprivation (STAND) - Rahul Aggarwal

Details
Charles Ryan sits down with Rahul Aggarwal to discuss one of the first of its kind, the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic providing comprehensive care to men with prostate cancer who are receiving androgen deprivation therapy (ADT). While ADT is extremely effective, it causes side effects, including fatigue, hot flashes, and sexual changes, such as decreased libido (se...

Testosterone Replacement in the Treatment of Advanced Prostate Cancer - Sam Denmeade and Michael Schweizer

Details
Sam Denmeade and Michael Schweizer join Charles Ryan at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss testosterone replacement in advanced prostate cancer. The three discuss the impact of testosterone on prostate cancer cells, recent clinical trials involving testosterone replacement and the risks and benefits of adding this therapy to one’s treatment plan for prostate cancer p...

Recurrent Disease After Radiation Therapy, the Role of the Radiation Oncologist - Felix Feng and Piet Ost

Details
Piet Ost and Felix Feng discuss the role of the radiation oncologist with regards to recurrent disease after radiation therapy. The two radiation oncologists debated the different approaches of treating patients who have a local recurrence compared to patients who have regional distant metastasis. Biographies: Felix Feng, MD, Associate Professor of Radiation Oncology, Urology; and Medicine, Univer...

An Update on the PRONOUNCE Trial, Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease - Susan Slovin

Details
Susan Slovin joins Alicia Morgans to provide an update on the PRONOUNCE trial, the first Phase III prospective trial comparing a GnRH antagonist with a GnRH agonist with the endpoints of major adverse cardiovascular events. It explores how cardiovascular disease is not only affecting our patient's wellbeing on androgen deprivation therapy but also gives us for the first time a lot of different end...

Advanced Prostate Cancer Clinic: What’s Changing? - Maha Hussain

Details
Maha Hussain highlights the pearls in the treatment landscape of metastatic hormone-sensitive, castration-resistant, and non-metastatic castration-resistant disease that came out of the last few years in prostate cancer in terms of the evolution of therapeutics. She details a plethora of clinical trials that had led to significant clinical benefit for patients, primarily overall survival advantage...

Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis

Details
Christopher Logothetis and Charles Ryan review key takeaways from Christopher Logothetis's Advanced Prostate Cancer Consensus Conference (APCCC 2019) presentation on Ethnicity and Prognosis of Prostate Cancer and the importance in understanding the differences in outcomes of individuals with the disease based on race and ethnicity. In his work Dr. Logothetis prepared for APCCC 2019, he presses the...

Management of Advanced Prostate Cancer in the Middle East - Deborah Mukherji

Details
Deborah Mukherji sits down with Carmel Pezaro at the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to share her perspective on how prostate cancer care in the Middle East, specifically Lebanon, compares to the rest of the globe. They discuss the impact and the potential of genomic testing and the use of novel imaging, such as PSMA PET/CT relevant to work in the Middle East and in Leba...
email news signup